ArticleJournal of translational medicine2026
Metformin attenuates developmental myelination.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundDevelopmental myelination is a protracted process spanning almost three decades. Many regions of the brain undergo developmental myelination throughout childhood and adolescence. Cognitive, motor, and behavioral performance rely on precise spatiotemporal development of myelin. Metformin, an FDA-approved treatment for Type II Diabetes Mellitus, can play a neuroprotective role in adult and aged rodent models of myelin loss by increasing oligodendrocyte production, modulating neuroinflammation, and accelerating myelin repair. However, metformin's ability to influence developmental myelination remains largely unknown, in spite of its approval for use in children aged 10 years and older.
methodsIn this study we investigated the ability of metformin to impact developmental myelination by delivering it either during myelination onset, or during a period of rapid myelination. In addition, we delivered metformin to isolated primary oligodendrocyte progenitor cells and newly-formed oligodendrocytes, and studied oligodendrocyte differentiation and myelin membrane outgrowth.
resultsWe found that metformin treatment attenuated myelination in anterior white matter regions in juvenile mice compared to control littermates, despite leaving oligodendrocyte densities unchanged. Analysis of myelin ultrastructure further revealed that metformin treatment led to fewer axons being myelinated and an increase in aberrant myelin structures. Using primary oligodendrocyte cultures, we found that newly-differentiated oligodendrocytes treated with metformin developed myelin sheets that were ~ 50% smaller compared to controls, without affecting the total number of Olig2 + or MBP+ oligodendrocytes.
conclusionsThese results suggest that during development, metformin restricts the myelinogenic capacity of individual oligodendrocytes but does not influence oligodendrocyte production. These findings have implications for the clinical use of metformin in young patients in which myelination is ongoing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.